AMGEN & TAKEDA
[BIZ/LIFE-SCI: Aachen, February 4] On another front, Takeda has decided to partner Amgen on the Motesanib cancer drug, paying initially USD 100m and USD 175m in a schedule of later payment. Amgen announced plans to license out some of its drugs last summer when sales dropped and now it’s launching its first cost-cutting move which is extremely interesting from the point of view of Amgen.
The world’s biggest biotech business Amgen and Japan’s Takeda pharmaceutical company have concluded a deal worth a billion dollars in pharmaceutical research, which will improve Takeda’s position on the Japanese market. Amgen is selling the Japanese rights of 13 experimental therapies to Takeda in a deal which is expected to be worth more than USD 1bn. Takeda is putting up USD 200m initially and contributing USD 340m to worldwide research costs. This is a major development in the biologics market. It also includes USD 360m in milestone payments and a deal to acquire Amgen KK which is Amgen’s Japanese subsidiary.
http://www.handelsblatt.de/